Results 41 to 50 of about 3,591 (213)

Bone and ocular safety of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a 52-week randomized study

open access: yesRespiratory Research, 2019
Background Long-term use of inhaled corticosteroids (ICSs) has been associated with increased risk of bone and ocular comorbidities. We evaluated the effects of the triple fixed-dose combination budesonide/glycopyrrolate/formoterol fumarate metered dose ...
Edward M. Kerwin   +4 more
doaj   +1 more source

Effects of Solvents on Skin Permeation of Formoterol Fumarate

open access: yesBiological and Pharmaceutical Bulletin, 2006
Effects of various chemicals applied as penetration enhancers on the permeation of formoterol fumarate (FF) across excised rat skin were investigated. Remarkable enhancement was noted with terpenes, fatty acid esters, and higher alcohols, whereas no significant influence was observed in the case of lower alcohols, pyrrolidones, and amines.
Ikuhiro, Kakubari   +5 more
openaire   +3 more sources

Non-interventional study of the safety and effectiveness of fluticasone propionate/formoterol fumarate in real-world asthma management

open access: yesTherapeutic Advances in Respiratory Disease, 2018
Introduction: In recognition of the value of long-term real-world data, a postauthorization safety study of the inhaled corticosteroid (ICS) fluticasone propionate and long-acting β 2 -agonist (LABA) formoterol fumarate (fluticasone/formoterol; Flutiform
Vibeke Backer   +11 more
doaj   +1 more source

Addition of tiotropium to formoterol improves inspiratory muscle strength after exercise in COPD [PDF]

open access: yes, 2012
Background: the addition of tiotropium bromide (110) to formoterol fumarate (FOR) improves exercise performance in patients with chronic obstructive pulmonary disease (COPD).
Canto, Nívea Dias do   +3 more
core   +2 more sources

Formoterol versus short-acting beta-agonists as relief medication for adults and children with asthma [PDF]

open access: yes, 2010
Background Formoterol is a long-acting beta(2)-agonist but because it has a fast onset of action it can also be used as a relief medication. Objectives To asses the efficacy and safety of formoterol as reliever therapy in comparison to short-acting ...
Cates, CJ, Welsh, EJ
core   +1 more source

Six‐Year Trends in Real‐World Data Use for Post‐Marketing Surveillance of New Medical Products in Japan

open access: yesClinical and Translational Science, Volume 19, Issue 2, February 2026.
ABSTRACT The Ministerial Ordinance on Good Post‐Marketing Study Practice for Drugs was amended by the Ministry of Health, Labour and Welfare (MHLW) in 2018 to clearly define post‐marketing database studies (DBS) as a measure of pharmacovigilance activities for approved medical products in Japan.
Suguru Okami   +2 more
wiley   +1 more source

Education in Family Medicine : What has been achieved? [PDF]

open access: yes, 2012
Contents: Education... historical landmarks - Pierre Mallia; The Malta College of Family Doctors and the Royal College of General Practitioners - John V.
Agius, Dominic   +2 more
core  

Single-inhaler triple therapy in patients with chronic obstructive pulmonary disease:a systematic review [PDF]

open access: yes, 2019
Background Guidelines recommend that treatment with a long-acting β2 agonist (LABA), a long-acting muscarinic antagonist (LAMA), and inhaled corticosteroids (ICS), i.e.
Chalmers, James D.   +6 more
core   +5 more sources

Effects of Multicomponent Interventions for Adults With Cancer Cachexia on Physical Function Outcomes

open access: yesJCSM Communications, Volume 9, Issue 1, January/June 2026.
ABSTRACT Introduction Progressive functional decline is a defining feature of cancer cachexia. We evaluated the effects of multicomponent interventions for adults with cancer cachexia on physical function outcomes. We also explored whether changes in physical function outcomes or overall quality of life varied following interventions with or without ...
Megan Bowers   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy